CSL Limited (CSLLY)
(Delayed Data from OTC)
$92.36 USD
+0.63 (0.69%)
Updated May 7, 2024 03:50 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CSLLY 92.36 +0.63(0.69%)
Will CSLLY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CSLLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CSLLY
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
New Strong Sell Stocks for August 14th
CSLLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Diverse Medical Stocks to Buy for 2023 and Beyond
What Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'
Other News for CSLLY
Ligand Reports First Quarter 2024 Financial Results
Grifols: Why To Watch From The Sidelines
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand